SCHEMBL23628969

SCHEMBL23628969

COC(=O)c1ccc(N)c(-c2ccccc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.58
EGFR P00533 1/20 0.57
ALDH1A1 P00352 5/20 0.54
HPGD P15428 4/20 0.54
GAA P10253 3/20 0.54
MAPT P10636 3/20 0.54
KDM4E B2RXH2 2/20 0.54
HSD17B10 Q99714 2/20 0.54
GLA P06280 1/20 0.54
CASP1 P29466 1/20 0.54
CASP7 P55210 1/20 0.54
ATM Q13315 1/20 0.54
PKM P14618 1/20 0.54
TSHR P16473 1/20 0.52
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
NPC1 O15118 1/20 0.50
LMNA P02545 1/20 0.50
PRKCZ Q05513 1/20 0.50
CFTR P13569 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2686505 0.87 EGFR (0.61) PTGS2EGFRALDH1A1HPGDGAA
SCHEMBL16107922 0.86 TDP1 (0.58) PTGS2EGFRALDH1A1HPGDGAA
SCHEMBL31054095 0.86 TDP1 (0.58) PTGS2EGFRALDH1A1HPGDGAA
SCHEMBL10458005 0.85 PTGS2 (0.76) PTGS2EGFRMAPTTSHRMEN1
SCHEMBL2721892 0.84 MAPT (0.57) PTGS2EGFRALDH1A1HPGDGAA
SCHEMBL443610 0.83 EGFR (0.52) PTGS2EGFRALDH1A1HPGDGAA
SCHEMBL821283 0.82 PTGS2 (0.59) PTGS2EGFRALDH1A1HPGDMAPT
SCHEMBL14832104 0.82 EGFR (0.68) PTGS2EGFRALDH1A1HPGDMAPT
SCHEMBL818748 0.82 PTGS2 (0.59) PTGS2EGFRALDH1A1HPGDGAA
SCHEMBL4198589 0.82 MAPT (0.49) PTGS2EGFRALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258342-B2 Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria UNIVERZA V LJUBLJANI (SI) 2025-03-25 US disclosed
US-20210323957-A1 NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA UNIVERZA V LJUBLJANI (SI) 2021-10-21 US disclosed
EP-3847172-A1 NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA Univerza v Ljubljani (SI) 2021-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323957-A1 NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA TOP1, TOP2A, TOP2B PTGS2 404/4885EGFR 3723/4885ALDH1A1 3249/4885
US-12258342-B2 Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria TOP1, TOP2A, TOP2B PTGS2 385/4885EGFR 3286/4885ALDH1A1 3339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.